Business Description
Intercept Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
I4P.GermanyICPT.MexicoICPT.USA IPO Date
2012-10-18Description
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.46 | |||||
| Equity-to-Asset | 0.17 | |||||
| Debt-to-Equity | 3.57 | |||||
| Debt-to-EBITDA | -2.4 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -4.25 | |||||
| Beneish M-Score | 0.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2 | |||||
| 3-Year EBITDA Growth Rate | 21.6 | |||||
| 3-Year EPS without NRI Growth Rate | 22 | |||||
| 3-Year FCF Growth Rate | 52.4 | |||||
| 3-Year Book Growth Rate | 12.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | 10.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 2.83 | |||||
| 9-Day RSI | 11.03 | |||||
| 14-Day RSI | 20.85 | |||||
| 6-1 Month Momentum % | 18.38 | |||||
| 12-1 Month Momentum % | 14.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.35 | |||||
| Quick Ratio | 2.35 | |||||
| Cash Ratio | 2.11 | |||||
| Days Sales Outstanding | 35.91 | |||||
| Days Payable | 3613.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.1 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 99.52 | |||||
| Operating Margin % | -16.43 | |||||
| Net Margin % | 70.39 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 41.98 | |||||
| ROIC % | -49.36 | |||||
| ROC (Joel Greenblatt) % | -4005.18 | |||||
| ROCE % | -40.45 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 2.12 | |||||
| Price-to-Owner-Earnings | 2.34 | |||||
| PS Ratio | 1.44 | |||||
| PB Ratio | 6.11 | |||||
| Price-to-Tangible-Book | 5.97 | |||||
| EV-to-EBIT | -3 | |||||
| EV-to-Forward-EBIT | -13.48 | |||||
| EV-to-EBITDA | -3.01 | |||||
| EV-to-Forward-EBITDA | -13.93 | |||||
| EV-to-Revenue | 1.33 | |||||
| EV-to-Forward-Revenue | 1.26 | |||||
| EV-to-FCF | -15.27 | |||||
| Price-to-Median-PS-Value | 0.08 | |||||
| Price-to-Net-Current-Asset-Value | 6.99 | |||||
| Price-to-Net-Cash | 22.19 | |||||
| Earnings Yield (Greenblatt) % | -33.33 |
How Intercept Pharmaceuticals Inc (FRA:I4P) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 299.573 | ||
| EPS (TTM) (€) | 6.642 | ||
| Beta | 0.98 | ||
| Volatility % | 69.89 | ||
| 14-Day RSI | 20.85 | ||
| 14-Day ATR (€) | 0.516993 | ||
| 20-Day SMA (€) | 16.40725 | ||
| 12-1 Month Momentum % | 14.56 | ||
| 52-Week Range (€) | 10.555 - 20 | ||
| Shares Outstanding (Mil) | 41.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intercept Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Intercept Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Intercept Pharmaceuticals Inc Frequently Asked Questions
What is Intercept Pharmaceuticals Inc(FRA:I4P)'s stock price today?
The current price of FRA:I4P is €12.65. The 52 week high of FRA:I4P is €20.00 and 52 week low is €10.56.
When is next earnings date of Intercept Pharmaceuticals Inc(FRA:I4P)?
The next earnings date of Intercept Pharmaceuticals Inc(FRA:I4P) is 2023-05-05 Est..
Does Intercept Pharmaceuticals Inc(FRA:I4P) pay dividends? If so, how much?
Intercept Pharmaceuticals Inc(FRA:I4P) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
